Assessing response to interferon-β in a multicenter dataset of patients with MS
Article 2016 en
Authors
MS
Maria Pia Sormani
CG
Claudio Gasperini
MR
Marzia Romeo
Abstract
1 min read
Substantial MRI activity, particularly if in combination with clinical relapses, during the first year of treatment with interferon-β indicates significant risk of treatment failure and EDSS worsening in the short term.
Ermelinda De Meo, Massimo Filippi, Vincenzo Brescia Morra, Francesco Patti, Giorgia Teresa Maniscalco, Valentina Torri Clerici, Giuseppe Salemi, Marco Onofrj, Giacomo Lus, Marta Simone, María Trojano, Maria Pia Amato
Hans-Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, Giancarlo Comi, Stuart D. Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, K. Beckmann, Brigitte Stemper, Gustavo Cruz, Rupert Sandbrink, Christoph Pohl
Serena Ruggieri, Luca Prosperini, Sarmad Al‐Araji, Pietro Annovazzi, Alvino Bisecco, Olga Ciccarelli, Nicola De Stefano, Massimo Filippi, Vinzenz Fleischer, Nikos Evangelou, Christian Enzinger, Antonio Gallo, Afagh Garjani, Sergiu Groppa, Shalom Haggiag, Michael Khalil, Matteo Lucchini, Massimiliano Mirabella, Xavier Montalbán, Carlo Pozzilli, Paolo Preziosa, Jordi Río, Maria A. Rocca,
Claudio Gasperini, Luca Prosperini, Mar Tintoré, Maria Pia Sormani, Massimo Filippi, Jordi Río, Jacqueline Palace, Maria A. Rocca, Olga Ciccarelli, Frederik Barkhof, Jaume Sastre‐Garriga, Hugo Vrenken, Jette Lautrup Frederiksen, Tarek Yousry, Christian Enzinger, Àlex Rovira, Ludwig Kappos, Carlo Pozzilli, Xavier Montalbán, Nicola De Stefano
Discussion(0)
No comments yet. Be the first to comment.